Lonza News Jun 5, 2026 Lonza and Stipple Bio partner to advance next-generation precision oncology ADC therapies - Indian Pharma Post
Lonza News Jun 4, 2026 Stipple Bio and Lonza Agree to Focus on Advancing Oncology ADC Therapies - Genetic Engineering and Biotechnology News
Lonza News Jun 4, 2026 Stipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies - The Manila Times
Lonza News Jun 4, 2026 Stipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies - The Manila Times
Lonza News Jun 4, 2026 Stipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies - Yahoo Finance Singapore
Lonza News Jun 4, 2026 Lonza advances integrated DNA‑to‑IND programmes with acceleration, derisking and innovation - Manufacturing Chemist
Lonza News May 28, 2026 Adaptable manufacturing platforms enable in vivo mRNA-LNP delivery, says Lonza - BioXconomy
Lonza News May 20, 2026 Oxford Nanopore (LON: ONT) and Lonza Launch Direct RNA Sequencing Solution for GMP mRNA Quality Control - foreignpolicyjournal.com
Lonza News May 20, 2026 Oxford Nanopore and Lonza Launch mRNA QC Solution for GMP Testing - Contract Pharma
Lonza News May 19, 2026 Global Cell Culture Media Market Outlook 2026-2036: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG - Yahoo Finance Singapore
Lonza News May 19, 2026 Lonza Group AG stock (CH0013841017): pharma supplier in focus after 2025 results and dividend decisi - AD HOC NEWS
Lonza News May 18, 2026 Bristol Myers Squibb Bolsters Oncology Pipeline with Lonza Licensing Agreement - CHEManager
Lonza News May 18, 2026 Lonza Group AG stock (CH0013841017): focus shifts to growth after strategic review and margin reset - AD HOC NEWS
Lonza News May 15, 2026 Active Pharmaceutical Ingredient Market Is Going to Boom | BASF, Lonza - openPR.com